Loading...
Loading...
Cynapsus Therapeutics Inc.
CYNA today announced the presentation of updated clinical data from the Phase 2 trial of APL-130277 in five poster presentations at the XXI World Congress on Parkinson's Disease and Related Disorders ("IAPRD") Meeting in Milan, Italy. These results showed APL-130277 significantly improved PD symptoms (as measured by MDS-UPDRS Part III), rapidly turning patients from the OFF to ON state and was generally safe and well-tolerated. "These additional Phase 2 data presented at the World Congress further support the potential of APL-130277 to rapidly convert patients with motor fluctuations from a debilitating OFF state to ON," said Dr. Albert Agro, Chief Medical Officer of Cynapsus. "We are encouraged by the clinical profile demonstrated to-date and the possibility to offer a treatment alternative for patients who suffer with Parkinson's disease. We continue to enroll patients in our pivotal Phase 3 efficacy and safety studies, and expect to share top-line data in mid-to-late 2016. We also
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in